Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Insulet Launches Omnipod 5 US-Wide Following Trial Period

Executive Summary

After six months, the Omnipod 5 has seen its limited market launch expanded to cover the entirety of the US market.

You may also be interested in...



Battery Issues Result In Recall Of Insulet’s Omnipod DASH Diabetes Manager

Insulet has recalled its Omnipod DASH personal diabetes manager after reports from users of battery issues. The company says it is replacing the devices.

Insulet Receives FDA Clearance For Omnipod For Children Ages 2 And Up

Insulet widens the launch of its Omnipod 5 automated insulin delivery system with the FDA clearance for children ages 2 and up. Previously, the system was available to people aged 6 years and older.

Dexcom Kiboshes Insulet Merger Rumors

Bloomberg reported on 23 May that Dexcom is considering acquiring Insulet to become a diabetes tech giant. Dexcom said on 31 May that it is not in “active discussions” about a merger with anyone right now.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel